The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Hims & Hers Health's 9-Day RSI or its related term are showing as below:
HIMS's 9-Day RSI is ranked worse than 87.21% of 1048
companies
in the Drug Manufacturers industry
Industry Median: 51.745
vs HIMS: 70.17
Hims & Hers Health (NYSE:HIMS) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Hims & Hers Health 9-Day RSI Related Terms
HIMS vs LNTH, LQDA, ALKS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's 9-Day RSI falls into.
Hims & Hers Health (NYSE:HIMS) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hims & Hers Health (HIMS) has a 9-Day RSI of 70.17 as of Jul. 04, 2026. According to the industry distribution chart, Hims & Hers Health ranks #914 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 87.2%.
Is Hims & Hers Health's 9-Day RSI too high?
Hims & Hers Health's current 9-Day RSI is 70.17. The Drug Manufacturers industry median 9-Day RSI is 51.75. Hims & Hers Health's value of 70.17 is 35.6% above this industry median. Based on the distribution chart, Hims & Hers Health ranks #914 out of 1048 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hims & Hers Health has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's 9-Day RSI compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #914 out of 1048 companies for 9-Day RSI. This places Hims & Hers Health in the lower half of its industry. The industry median 9-Day RSI is 51.75. Hims & Hers Health's value of 70.17 is 35.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 51.75, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hims & Hers Health's current 9-Day RSI of 70.17 is 35.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 51.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current 9-Day RSI is 70.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Fairly Valued. The stock's GF Value™ is $39.04, compared to a current price of $36.80 — trading 5.7% below its estimated fair value. The current 9-Day RSI is 70.17 and 35.6% above the Drug Manufacturers industry median of 51.75. Hims & Hers Health's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current 9-Day RSI is 70.17 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of $36.80 is trading 5.7% below its estimated GF Value™ of $39.04.
GuruFocus considers Hims & Hers Health to be Fairly Valued.
Key valuation signals for HIMS:
9-Day RSI: 70.17
GF Value™: $39.04 vs. price of $36.80 (5.7% below fair value)
Industry Position: 35.6% above the Drug Manufacturers median (#914 of 1048)
No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
81GF Score
Get the complete analysis for HIMS
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIMS has been successfully added to your 